



Oncology Venture

## Investor news

### CEO Letter from Steve Carchedi

Dear shareholders,

I have just completed my first roadshow as CEO of Oncology Venture. Together with the company's new CFO Henrik Moltke, I have met with investors in both Sweden and Denmark, and it has been a great pleasure to visit Stockholm, Gothenburg, Malmo and Copenhagen. The trip has prompted me to write this brief CEO letter to you, our investor community of both current and prospective shareholders.

At all the venues, I must say I have been positively surprised by the in-depth knowledge of the company that many of you have. In addition, many investors have shared their hopes and vision that this will become a truly successful company, making a real change for patients, healthcare professionals and shareholders.

#### **A new focused strategy**

This level of commitment and interest from the shareholder community here in Scandinavia has only made my own personal commitment to making this company a success even deeper.

For those of you, who did not have the chance to study the published prospectus; please, allow me to list four important changes that are fundamental to how we manage the company as a part of our new strategy:

- Focused development of the pipeline, giving highest priority to the development of Dovitinib, Ixempra, and 2X-121
- Commercialization of the company's technology is our fundamental goal
- Predictable financials: We will use investor funds prudently, efficiently and ensure solid financial controls.
- Drive shareholder value

#### **Watch full presentation**

If you were not able to attend any of the meetings on the roadshow, I'd like to share a few options you have to learn more about our new strategy and in what direction, I will take the company in the years to come. On the frontpage of our website, you'll find:

- A video from our online investor presentation (direct link: <https://youtu.be/qIMJraIRfBo>)
- The slides from the presentation as a PDF (direct link: <http://bit.ly/OV-new-strategy>)

If you have time, and would like to watch the presentation at a live event, where I also will be taking questions, we have scheduled an online investor presentation today Thursday at 7 pm CET.

You can sign up for the online event on Thursday here: <http://bit.ly/OV-investor-presentation>  
Feel free to send me questions in advance of the online event at [webcast@oncologyventure.com](mailto:webcast@oncologyventure.com), and we will be able to answer as many as possible.

Finally, I'd like to mention that the subscription period for our rights issue is coming to an end. If you choose to subscribe, you'll also get warrants at no cost, which may be exercised during the next 24 months.

I am thankful for your interest in the company, and I hope that I will have the chance to meet many shareholders again on future roadshows. At that point in time, I will be able to tell about the progress we will have achieved. I look very much forward to it.

Yours sincerely,

Steve

Steve Carchedi  
CEO of Oncology Venture A/S

**For further information, please contact:**

**For investor inquiries**

Henrik Moltke, CFO

E-mail: [hm@oncologyventure.com](mailto:hm@oncologyventure.com)

Telephone +45 53 63 96 37

**About Oncology Venture A/S**

Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, DRP®. The company has a mature portfolio of seven drug candidates, including compounds in the pre-registration stage.

The current product portfolio includes: 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast and ovarian cancer; dovitinib, which will enter Phase 2 trials for indications dependent on further Dovitinib-DRP retrospective/prospective analysis of studies completed by Novartis: Ixabepilone for the treatment of breast cancer. LiPlaCis®, a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast and prostate cancer 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; irofulven, a Phase 2 is ongoing for prostate cancer; and APO010, an immuno-oncology product in Phase 1/2 for multiple myeloma.

**About the Drug Response Predictor – DRP® Companion Diagnostic**

Oncology Venture uses its multi gene DRP® to select those patients who by the genetic signature of their cancer are found to have a high likelihood of responding to the drug. By screening patients before treatment the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology. DRP® is based on messenger RNA from the patient's biopsies.

DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined.

The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.

Learn more at [oncologyventure.com](http://oncologyventure.com).

Follow us on social media:

Facebook: <https://www.facebook.com/oncologyventure/>

LinkedIn: <https://www.linkedin.com/company/oncology-venture/>

Twitter: <https://twitter.com/OncologyVenture>